Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
We now rank 3rd in pharmaceutical production by volume and 14th by value
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated